Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China

• DOI: 10.18632/oncotarget.16293
• Publication Date: 2017-03-17T04:08:31Z
• Authors: Feng Li; Zhichao Liao; Jun Zhao; Gang Zhao; Xubin Li; Xiaoling Du; Yun Yang; Jilong Yang
• Keywords: Apatinib

// Feng Li 1,2 , Zhichao Liao Jun Zhao Gang 2,3 Xubin 2,4 Xiaoling Du 5 Yun Yang and Jilong 1 Department of Bone Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic China 2 National Clinical Research Center Cancer, 3 Pathology, 4 Radiology, Diagnostics, University, Correspondence to: Yang, email: Keywords : sarcoma; Apatinib; efficacy; progression free survival; clinical benefit response Received October 06, 2016 Accepted March 01, 2017 Published 16, Abstract Purpose: This study was conducted to review the efficacy safety Apatinib in stage IV sarcoma patients who failed previous chemotherapy. Materials Methods: The information on 16 with sarcomas prior chemotherapy subsequently received treatment collected. given 500mg/daily weeks as a cycle. All had at least one measurable extracranial tumor according Response Evaluation Criteria In Solid Tumors 1.0 criteria. Progression survival (PFS), overall (OS), objective rate (ORR), disease control (DCR) treatment-related adverse effects (AEs) were reviewed evaluated. Results: Patients administered for 0 9 cycles median 3.2 cycles. Median follow-up time 8.4 months (1 12 months). Ten complete cycle eligible analysis. PFS 8.84 months. Two achieved partial (PR) 6 stable (SD). evaluated (PD) patient died progression. ORR 20.0% (2/10) DCR 80.0% (8/10). most common grade 3/4 AEs hypertension (18.7%), hand-foot syndrome (12.5%) proteinuria (6.3%). No drug-related severe occurred. Conclusion: this exploratory exhibited manageable toxicity result supports future random controlled trial further define activity sarcomas.